Macular degeneration

This study tests an experimental drug called AVD-104, given as an eye injection, for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The trial involves 300 participants and aims to see if the drug is safe and can slow …

This study tests a new drug called zifibancimig for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is given either as an eye injection or through a small implant placed in the eye that releases the drug over time. The trial involv…

This study looks at how well a biosimilar drug called Yesafili works for people with wet age-related macular degeneration (AMD). About 54 participants will switch from the standard drug Eylea to Yesafili. Doctors will check vision and eye health to see if the biosimilar is a safe…

This study tests whether a home eye-scanning device can improve care for people with wet age-related macular degeneration (AMD) who are switching to the medication faricimab. Participants will scan their own retinas at home several times a week, and the images will be sent to the…

This early feasibility trial tests a new retinal implant called PRIMA in 5 people with advanced dry age-related macular degeneration who have lost central vision. The device is surgically placed in the eye to stimulate remaining retinal cells. Researchers are checking if it is sa…

This clinical trial is testing whether an experimental eye injection called ONS-5010 (bevacizumab) can help preserve vision in people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study will compare ONS-5010 to an existing treatment, ranibiz…

This trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. Abo…

This early-stage trial tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 30 participants receive eye injections of K8 and are monitored for 26 weeks to check s…

This study tests the safety of an experimental eye injection called ONS-5010 (bevacizumab) in people with vision loss from wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. Participants receive the injection and are monitored for side…

This study tests whether switching to a higher dose (8mg) of aflibercept can help people with wet age-related macular degeneration (AMD) who have not responded well to standard treatments like faricimab or the usual 2mg dose of aflibercept. Participants receive up to three inject…

This study investigates whether a non-invasive light treatment called photobiomodulation can improve vision and slow vision loss in people with dry age-related macular degeneration (AMD). Participants receive either active light therapy or a sham (inactive) treatment over 12 mont…

This early-phase trial tested NT-101 eye drops in 20 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study aimed to check safety and see if the drops could reduce fluid buildup and improve vision. Participants received either a low or h…

This study checks the long-term safety of an eye injection called avacincaptad pegol for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 278 adults who finished a previous study of this drug will receive the injec…

This study tested whether a pre-filled syringe of the medicine SB11 (a biosimilar to ranibizumab) is easy for eye doctors to use. Thirty adults with wet age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received on…

This study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and can improve or maintain vision. Participants used the drops for a set period, and their vision was measured aft…

This early-stage trial tested a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels damage central vision. The therapy was injected into the eye to block these vessels. The main goal was to check s…

This study tested a tiny implant called the PRIMA Bionic Vision System in 5 people with advanced dry age-related macular degeneration who had lost central vision. The implant is placed under the retina and uses electrical stimulation to replace damaged light-sensing cells. The go…

This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whet…

This study tested a gene therapy called JNJ-81201887 in 305 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The treatment is injected into the eye and aims to slow the growth of damaged areas. Researchers measured chan…

This study tested whether injecting a concentrated form of a patient's own blood, called platelet-rich plasma (PRP), into the eye could slow the progression of advanced dry age-related macular degeneration (AMD). Fourteen people with advanced dry AMD received three PRP injections…

This study tested a drug called pegcetacoplan, given as an eye injection using a prefilled syringe, in 44 people with geographic atrophy (a form of advanced age-related macular degeneration). The main goal was to see if the new syringe is safe and easy for doctors to use. The dru…

This study tested a new medicine called BAT5906 against a standard treatment (Lucentis) for wet age-related macular degeneration, a condition that can cause rapid vision loss. 488 adults aged 50-85 with active disease received either BAT5906 or Lucentis injections into the eye. T…

This study tested whether adding a light-based treatment (photodynamic therapy) to the standard drug ranibizumab could reduce the number of eye injections needed for wet macular degeneration. Sixty adults over age 50 with the condition took part. The goal was to see if the combin…

This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two…

This study tested whether the antibiotic minocycline, taken as a pill twice daily for at least 3 years, could safely slow the growth of geographic atrophy—an advanced form of age-related macular degeneration that causes blind spots. Thirty-seven adults aged 55 and older with geog…

This study tests a daily pill called ALK-001, a modified form of vitamin A, to see if it can slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 300 people with the condition took either the drug or a place…

This study tested an eye injection called Zimura (avacincaptad pegol) in 448 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes permanent vision loss. The goal was to see if the drug could slow the growth of damaged areas in the retin…

This study compared two different dosing schedules of brolucizumab (Beovu) in 52 people with wet age-related macular degeneration (AMD) who had not responded well to previous treatment. Participants received the drug as an eye injection either on a fixed schedule or with adjustme…

This phase 2 trial tested carbidopa-levodopa (Sinemet), a drug usually used for Parkinson's disease, in 20 people with wet age-related macular degeneration (AMD). The goal was to see if the drug is safe and can improve vision or reduce retinal swelling. Participants took the pill…

This phase 2 trial tested carbidopa-levodopa, a drug used for Parkinson's disease, in 35 people with wet age-related macular degeneration (AMD). The goal was to see if the drug could improve vision and reduce the need for standard anti-VEGF eye injections. Participants took the o…

This phase 3 trial tested whether a new drug called ABP 938 works as well as the standard treatment Eylea for wet age-related macular degeneration (AMD), a leading cause of vision loss. 576 adults aged 50 and older with wet AMD received injections of either ABP 938 or Eylea every…

This study tests a drug called carbidopa-levodopa (Sinemet), typically used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It is a 9-month extension for 35 participants who completed an earlier study. The goal is to see if the drug can help ma…

This phase 2 trial tested a new way to deliver dexamethasone directly to the back of the eye using tiny microspheres (OXU-001) compared to the standard Ozurdex implant. The study enrolled only 3 adults with diabetic macular edema to check safety and how well the treatment is tole…

This study tested a robotic stabilizer to help surgeons inject a clot-busting drug (tPA) under the retina in 20 patients with bleeding from age-related macular degeneration. The robot held the needle steady for up to 3 minutes during standard surgery. The main goals were to see i…

This study tests whether a smartphone-based camera can accurately screen for eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration. About 550 patients will have photos taken with both the smartphone camera and standard equipment. Ophthalmologis…

This study tested an artificial intelligence (AI) algorithm to detect diabetic retinopathy and glaucoma from eye photos. Researchers compared the AI's accuracy to that of family doctors and retina specialists. The goal was to see if AI could be a reliable screening tool in primar…

This study tested whether an AI tool can help eye doctors diagnose four common retinal diseases (diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, and glaucoma) more accurately and quickly. Ten doctors from five hospitals read fundus images both with…

This study tested a new device called CRYSTALSIGHT that uses eye-tracking and artificial intelligence to monitor macular diseases like age-related macular degeneration and diabetic retinopathy. Twenty participants used the device at home to see if it could accurately track eye mo…

This study tested whether a device called MAIA, which measures light sensitivity in the retina, can predict when intermediate age-related macular degeneration (AMD) progresses to the advanced stage. Researchers followed 182 people who already had advanced AMD in one eye and inter…

This study tested whether injections of aflibercept (Eylea) into the eye could prevent the development of wet age-related macular degeneration (AMD) in people at high risk. 128 participants with early signs of AMD in one eye and wet AMD in the other eye received either Eylea or a…

This trial tests whether a new anesthetic gel, Iheezo, reduces discomfort during intravitreal injections compared to standard numbing drops. Fifty patients receiving injections in both eyes on the same day will have one eye treated with Iheezo and the other with standard anesthes…

This study looked at whether a treatment called transscleral lutein iontophoresis (TSLI) is safe and helpful for people with a specific type of age-related macular degeneration (AMD) that includes reticular pseudodrusen. Thirty participants received the treatment, and their visio…

This study tested whether a steroid eye drop (loteprednol) can reduce pain after intravitreal injections for age-related macular degeneration. 64 participants received either the steroid drop or artificial tears right after their injection. Pain was tracked by phone over a week. …

This completed study followed 26 adults aged 55 and older with early age-related macular degeneration (AMD) or healthy eyes for up to 5 years. Researchers used eye exams, imaging, and vision tests to track changes in the retina and visual function. The goal was to better understa…

This study followed 57 people with age-related macular degeneration (AMD) for up to 5 years to see how their eyes adjust to darkness. Participants had yearly eye exams and dark adaptation tests, where they sat in a dark room and pressed a button when they saw a light. The goal wa…

This study looks at X-linked juvenile retinoschisis (XLRS), a rare inherited eye disease that causes vision loss in young males. Researchers will examine 351 participants, including affected males and female carriers, using eye exams, retinal photos, and genetic tests. The goal i…

This study followed 20 adults aged 55 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes central vision loss. Researchers measured how the damaged area in the eye changed over nearly 4 years using eye exams and photos. The goal was…

This study looked at whether a simple test measuring how fast eyes recover in the dark can help track early to middle dry age-related macular degeneration (AMD). Researchers followed 217 adults aged 50 and older, with or without AMD, for up to 5 years. The goal was to see if chan…

This study tests whether a special camera called the OcuMet Beacon can detect stressed cells in the retina of people with geographic atrophy, an advanced form of age-related macular degeneration. Researchers want to see if the patterns of stress match areas of damage seen on stan…

This study compared two different eye imaging machines (Clarus and Optos) to see how well they measure geographic atrophy, a form of vision loss from age-related macular degeneration. Researchers enrolled 62 patients and took images with each device, then compared the measurement…

This study looks at what people with age-related macular degeneration (AMD) know about their disease and what they need to manage it better. Researchers will survey and interview 118 patients to understand their knowledge, daily challenges, and support needs. The goal is to use t…

This study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see…

This study followed 516 older adults in France for 8 years to see how many develop age-related macular degeneration (AMD), a leading cause of blindness. Researchers used eye exams and imaging to track the disease and look for risk factors like genetics and lifestyle. The goal is …

This study examined how vision loss progresses in people with geographic atrophy, an advanced form of dry age-related macular degeneration. Researchers analyzed past medical records and eye images from 60 patients to see which retinal changes are linked to faster vision decline. …

This completed study collected eye images from 1,000 people with intermediate age-related macular degeneration (AMD) to create a detailed database. Researchers will analyze these images to find signs that predict whether the disease will worsen to advanced stages. The goal is to …

This study tested four different approaches to find and treat eye diseases like cataracts, glaucoma, and diabetic retinopathy in communities in Nepal. Over 87,000 people aged 50 and older took part. The goal was to see which method—comprehensive screening, cataract camps, communi…

This study looked at how much of a burden patients feel from repeated anti-VEGF eye injections for three different eye diseases: wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Researchers surveyed 393 patients about their treatment burde…

This study looked at proteins in the eye fluid of 100 people with wet age-related macular degeneration (AMD). The goal was to measure certain growth factors that might explain why about 37% of patients do not respond well to standard anti-VEGF injections. Researchers collected a …

This study looked at 30 patients with a type of age-related macular degeneration (AMD) to see how treatment affects the barrier between blood and eye fluid. Researchers measured protein levels in the eye fluid before and during anti-angiogenic therapy. The goal was to better unde…

This study looked at two ways of monitoring wet age-related macular degeneration (AMD) using eye scans: standard OCT B-scans and a newer technique called OCT angiography. The goal was to see if the newer scan could better detect when the disease is active, helping doctors decide …

This study created a national DNA and blood repository for inherited eye diseases like retinitis pigmentosa. Over 6,600 participants provided blood samples and eye exam data to help researchers identify genetic causes. The stored samples are available to scientists without person…

This completed study examined inflammation markers in the fluid from the eyes of 82 people with different stages of age-related macular degeneration (AMD) and a control group without AMD. Researchers collected samples during cataract surgery and tested for 27 inflammation-related…

This study looked at new ways to measure and train eye movements in 21 people with macular degeneration, a condition that causes central vision loss. The goal was to see if training could help them use their remaining side vision more effectively. The research focused on understa…

This study looked at 470 people with age-related macular degeneration (AMD) to see if special eye scans (SDOCT) can predict vision loss and disease worsening. Participants were already in the AREDS 2 trial and had moderate to high risk of progression. Researchers tracked changes …

This study looked at 100 older adults (60+) to see if those with severe vision loss from age-related macular degeneration have more shoulder pain, stiffness, and movement problems compared to those with normal vision. Researchers measured pain, range of motion, and daily living a…

This study looked at whether telling healthy adults their genetic risk for age-related macular degeneration (AMD) encourages them to eat more carotenoid-rich foods, which are good for eye health. Eighty Caucasian participants aged 18 to 64 without AMD were given genetic risk info…

This completed study looked at 556 people to understand how night vision problems are connected to early age-related macular degeneration (AMD). Participants took vision tests and had detailed eye imaging. The goal was to find reliable markers that could help design future treatm…

This study tested whether personalized risk profiling (including genetic testing) and coaching can motivate people with age-related macular degeneration (AMD) to change their lifestyle. 150 participants received standard lifestyle advice plus supplements, and some also got person…